Prostate Cancer Tx Moving Closer to 'Precision Paradigm'

Also: zeroing in on the complex biology of mHSPC and how biomarkers may guide treatment selection | ASCO Reading Room Article Selection Thursday, September 21, 2023 FEATURED STUDY [Prostate Cancer Tx Moving Closer to 'Precision Paradigm']( [Also: zeroing in on the complex biology of mHSPC and how biomarkers may guide treatment selection]( Other Key News [Which Is More Cost Effective for Pancreatic Cancer: Neoadjuvant ChemoRT or Upfront Surgery?]( [Surprisingly, one was more costly, but still favored in 94% of resectable disease simulations, study showed]( [Diffuse Large B-Cell Lymphoma's Rapidly Evolving Treatment Landscape]( [More promising therapies]( for patients with [newly diagnosed and relapsed disease]( [Kidney Cancer: Finding Surgical Margins With Mass Spectrometry]( [Novel technology may overcome limitations of intraoperative frozen section]( [Lung Cancer and Depression: A Global Issue That Needs More Attention]( [Challenges and opportunities]( in cancer survivorship [in the Indo-Pacific]( © 2023 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Partner_ASCO_Reading_Room) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 Fifth Avenue 15th Floor New York, NY 10011